Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Mapping US FDA's Biosimilar Pathway With Pink Sheet Drug Review Profiles

Jul 26 2017

• By Bridget Silverman

Related Content

US Biosimilars: 40% First-Cycle Approval Rate Leaves Room For Improvement

Jul 06 2017

Mylan, Amgen Biosimilars Sail Through Advisory Panels, May Diverge From There

Jul 14 2017

How To Label A Biosimilar? Copy The Reference Product, FDA Told Sandoz

Jun 15 2015

Biosimilar Sponsors Took Delivery Device Shortcuts For Erelzi, Amjevita

Apr 20 2017

Sandoz’s Erelzi: Biosimilar Pediatric Labeling Strayed From Enbrel

Apr 20 2017

Novel Biologics In US Might Not Start Getting Suffixes Until August

Apr 05 2017

Samsung’s Renflexis: Second US Biosimilar To Janssen’s Remicade, With A Few Firsts

Apr 22 2017

Biosimilar Naming: FDA Asked Celltrion For Two Kinds Of Suffixes

Jul 15 2016

With Inflectra, FDA Showed Flexibility On Biosimilar Pediatric Study Plans

Jul 15 2016

Evolving Biosimilar Pathway Brings Mid-Review Policy Issues

Jul 15 2016

Inflectra Analytical Data Eased FDA's 'Residual Uncertainty' About Remicade Differences

Jul 15 2016

Biologic Product Naming: US FDA Sticks With Suffixes ‘Devoid Of Meaning’

Jan 13 2017

How To Name A Biosimilar: Amgen Persisted With Amjevita Suffix Despite FDA Doubts

Feb 20 2017

Sandoz Tested Erelzi’s Suffix On Multiple Fronts

Feb 20 2017

Related Companies

Amgen, Inc.

Novartis AG

Celltrion, Inc.

Additional Topics

United States Biosimilars Review Pathway Drug Review Regulation Drug Review Profile BioPharmaceutical

More from Drug Review Profiles

More from Product Reviews

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window